Loading
A phase 1/2 trial of Docetaxel, Ifinatamab deruxtecan, Opevesostat and Enzalutamide in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) is a phase 1/2 interventional study registered as NCT06863272 by Merck Sharp & Dohme LLC, with 360 participants planned, started 2025-07-03 and due to reach its primary completion in 2031-04-01. Interventions recorded: Docetaxel, Ifinatamab Deruxtecan, Opevesostat, Abiraterone, Enzalutamide and Rescue Medication.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Docetaxel, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Opevesostat, Docetaxel, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD) and the tag pipeline.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Docetaxel, Merck & Co. (MSD) and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Antibody-drug conjugate (ADC), Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/